JPH06500921A - ルシフェラーゼ組成物及び方法 - Google Patents
ルシフェラーゼ組成物及び方法Info
- Publication number
- JPH06500921A JPH06500921A JP3517531A JP51753191A JPH06500921A JP H06500921 A JPH06500921 A JP H06500921A JP 3517531 A JP3517531 A JP 3517531A JP 51753191 A JP51753191 A JP 51753191A JP H06500921 A JPH06500921 A JP H06500921A
- Authority
- JP
- Japan
- Prior art keywords
- luciferase
- concentration
- coa
- luciferin
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060001084 Luciferase Proteins 0.000 title claims description 226
- 239000005089 Luciferase Substances 0.000 title claims description 225
- 238000000034 method Methods 0.000 title claims description 80
- 239000000203 mixture Substances 0.000 title claims description 69
- 238000006243 chemical reaction Methods 0.000 claims description 118
- 241000254173 Coleoptera Species 0.000 claims description 100
- 239000000243 solution Substances 0.000 claims description 92
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 claims description 80
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 claims description 74
- 238000003556 assay Methods 0.000 claims description 73
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 claims description 72
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 claims description 72
- 230000000694 effects Effects 0.000 claims description 60
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 41
- 239000003774 sulfhydryl reagent Substances 0.000 claims description 41
- 238000004020 luminiscence type Methods 0.000 claims description 40
- 238000004519 manufacturing process Methods 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- -1 2-mercaptopropyl Chemical group 0.000 claims description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 9
- 230000005281 excited state Effects 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 8
- 239000003599 detergent Substances 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 7
- 239000012091 fetal bovine serum Substances 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 claims description 6
- 239000012491 analyte Substances 0.000 claims description 5
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 230000002934 lysing effect Effects 0.000 claims description 4
- 229920002113 octoxynol Polymers 0.000 claims description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 241000283690 Bos taurus Species 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 241000254064 Photinus pyralis Species 0.000 claims 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 241001061127 Thione Species 0.000 claims 2
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 claims 1
- QNNVICQPXUUBSN-UHFFFAOYSA-N 2-sulfanylpropan-1-ol Chemical compound CC(S)CO QNNVICQPXUUBSN-UHFFFAOYSA-N 0.000 claims 1
- SHLSSLVZXJBVHE-UHFFFAOYSA-N 3-sulfanylpropan-1-ol Chemical compound OCCCS SHLSSLVZXJBVHE-UHFFFAOYSA-N 0.000 claims 1
- 101500018492 Rhizopus oryzae Glucoamylase 2 Proteins 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 239000000395 magnesium oxide Substances 0.000 claims 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 89
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 89
- 239000005516 coenzyme A Substances 0.000 description 89
- 229940093530 coenzyme a Drugs 0.000 description 89
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 89
- 229940088598 enzyme Drugs 0.000 description 64
- 108090000790 Enzymes Proteins 0.000 description 63
- 102000004190 Enzymes Human genes 0.000 description 63
- 239000000523 sample Substances 0.000 description 23
- 239000000126 substance Substances 0.000 description 21
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 238000005415 bioluminescence Methods 0.000 description 15
- 230000029918 bioluminescence Effects 0.000 description 15
- 238000006555 catalytic reaction Methods 0.000 description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 14
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 239000010452 phosphate Substances 0.000 description 13
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 12
- 239000002853 nucleic acid probe Substances 0.000 description 12
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 10
- 239000007997 Tricine buffer Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000003149 assay kit Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 150000007970 thio esters Chemical class 0.000 description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 description 8
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical group [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 7
- 229940000489 arsenate Drugs 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 6
- 241000254158 Lampyridae Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000009849 deactivation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000005283 ground state Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108010008488 Glycylglycine Proteins 0.000 description 4
- 241001340896 Pyralis Species 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940043257 glycylglycine Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108090000363 Bacterial Luciferases Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 125000004956 cyclohexylene group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229940066429 octoxynol Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- AEELXMHQIJJMKP-QWWZWVQMSA-N (2r,3r)-3-sulfanylbutane-1,2,4-triol Chemical compound OC[C@@H](O)[C@H](S)CO AEELXMHQIJJMKP-QWWZWVQMSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000700108 Ctenophora <comb jellyfish phylum> Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241001427543 Elateridae Species 0.000 description 1
- 241001300226 Erylus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- 239000007996 HEPPS buffer Substances 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 1
- 241000254054 Luciola cruciata Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Detergent Compositions (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ルシフェラーゼを含むと思われるサンプル中で甲虫ルシフェラーゼの存在を 検出するための方法であって、(a)前記サンアルのアリコートを用い、ルシフ ェラーゼ−ルシフェリン反応中でルシフェラーゼの活性に有効な濃度で、ルシフ ェリン、アデノシン三リン酸、チオール試薬及びMg+2を含む溶液を作成し、 次いで(b)段階(a)から得られた溶液からの発光を測定することを含む該方 法。 2.段階(a)で作成した溶液中のチオール試薬が、CoA、ジチオトレイトー ル、ジチオエリトリトール、β−メルカプトエタノール、2−メルカプトプロパ ノール、3−メルカプトプロパノール、2.3−ジチオアロパノール及びグルク チオンからなる群から選択されることを特徴とする請求項1に記載の方法。 3.溶液がCoA及びCoA以外のチオール試薬を含むことを特徴とする請求項 2に記載の方法。 4.溶液がさらに蛋白質性のルシフェラーゼ−活性エンハンサーを含むことを特 徴とする請求項3に記載の方法。 5.CoA以外のチオール試薬がジチオトレイトールであることを特徴とする請 求項3に記載の方法。 6.CoA以外のチオール試薬がジチオトレイトールであり、ルシフェラーゼ− 活性エンハンサーがウシ胎児血清アルブミンであることを特徴とする請求項4に 記載の方法。 7.溶液中のCoA濃度が0.1mM〜10mMであり、ジチオトレイトール濃 度が5mM〜100mMであることを特徴とする請求項5に記載の方法。 8.溶液中のCoA濃度が0.1mM〜1.0mMであり、ジチオトレイトール 濃度が5mM〜100mMであり、及びウシ胎児血清アルブミン濃度が10μg /me〜5mg/meであることを特徴とする請求項6に記載の方法。 9.溶液中のATP濃度が0.mMh〜1mMであり、ルシフェリン濃度が0. 1mM〜1mMんであり、及びMg+2濃度が2mM〜15mMであることを特 徴とする請求項7に記載の方法。 10.溶液中のATP濃度が0.1mM〜1mMであり、ルシフェリン濃度が0 .1mM〜1mMであり、及びMg+2濃度が2mM〜15mMであることを特 徴とする請求項8に記載の方法。 11.甲虫ルシフェラーゼがP.pyralisルシフェラーゼであることを特 徴とする請求項1〜10のいずれか1項に記載の方法。 12.前記化合物を含むと思われるサンプル中のアデノシン三リン酸の存在を検 出するための方法であって、(a)前記サンプルのアリコートを用い、ルシフェ ラーゼールシフェリン反応でのルシフェラーゼの活性に有効な濃度で、甲虫ルシ フェラーゼ、ルシフェリン、チオール試薬及びMg+2を含む溶液を作成し、次 いで(b)段階(a)から得られた溶液からの蛍光を測定することを含む該方法 。 13.段階(a)で作成した溶液に於けるチオール試薬が、CoA、ジチオトレ イトール、ジチオエリトリトール、β−メルカプトエタノール、2−メルカプト プロパノール、3−メルカアトブロパノール、2,3−ジチオプロパノール及び グルタチオンからなる群から選択されることを特徴とする請求項12に記載の方 法。 14.溶液がCoA及びCoA以外のチオール試薬を合むことを特徴とする請求 項13に記載の方法。 15.溶液がさらに、蛋白質性のルシフェラーゼ−活性エンハンサーを含むこと を特徴とする請求項14に記載の方法。 16.CoA以外のチオール試薬がジチオトレイトールであることを特徴とする 請求項14に記載の方法。 17.CoA以外のチオール試薬がジチオトレイトールであり、ルシフェラーゼ −活性エンハンサーがウシ胎児血清アルブミンであることを特徴とする請求項1 5に記載の方法。 18.溶液中のCoA濃度が0.mM〜1.0mMであり、ジチオトレイトール 濃度が5mM〜100mMであることを特徴とする請求項16に記載の方法。 19.溶液中のCoA濃度が0.1mM〜1.0mMであり、ジチオトレイトー ル濃度が5mM〜100mMであり、ウシ胎児血清アルブミン濃度が10μg/ me〜5mg/meであることを特徴とする請求項17に記載の方法。 20.溶液中のルシフェリン濃度が0.1mM〜1mMであり、Mg+2濃度が 2mM〜15mMであることを特徴とする請求項18に記載の方法。 21.溶液中のルシフェリン濃度が0.mM〜1mMであり、M8+2濃度が2 mM〜15mであることを特徴とする請求項19に記載の方法。 22.甲虫ルシフェラーゼがP.ρyralisルシフェラーゼであることを特 徴とする請求項12〜21のいずれか1項に記載の方法。 23.ルシフェラーゼ−ルシフェリン反応を触媒し得る甲虫ルシフェラーゼ、C oA及びCoハ以外のチオール試薬を含むことを特徴とする組成物。 24.CoA濃度が0.mM〜1.mMであり、CoA以外のチオール試薬濃度 が5mM〜200mMであり、水溶液であることを特徴とする請求項23に記載 の組成物。 25.CoA以外のチオール試薬が濃度5mM〜100mMのジチオトレイトー ルであることを特徴とする請求項24に記載の組成物。 26.さらにウシ胎児血清アルブミンを濃度10μg/me〜5mg/meで含 むことを特徴とする請求項25に記載の組成物。 27.さらに2−アミノエタノールを濃度5mM〜50mMで、またはリン酸イ オンを濃度10mM〜60mMで含むことを特徴とする請求項26に記載の組成 物。 28.甲虫ルシフェラーゼがP.yralisルシフェラーゼであることを特徴 とする請求項23〜27のいずれか1項に記載の組成物。 29.さらに、(1)濃度2mM〜15mMのマグネシウムイオンと (2)濃度0.1mM〜1.mMのアデノシン三リン酸及び濃度0.1mM〜1 .mMのルシフェリンのいずれかまたは両方を含むことを特徴とする請求項28 に記載の組成物。 30.CoA、甲虫中で天然に存在するルシフェラーゼ及びルシフェラーゼ−ル シフェリン反応中の励起状態のオキシルシフェリンの結合体であって、細胞外で 存在する該結合体。 31.甲虫ルシフェラーゼがP.pyralisルシフェラーゼであることを特 徴とする請求項30の錯体。 32.ルシフェラーゼが天然に存在する細胞外でのルシフェリル−CoA。 33.チオール試薬、アデノシン三リン酸、ルシフェリン及びマグネシウムイオ ンを含むルシフェラーゼ−ルシフェリン反応組成物からなる、このようなルシフ ェラーゼを含むと思われるサンアル中に甲虫ルシフェラーゼの存在をアッセイす るための試験キット。 34.ルシフェラーゼ−ルシフェリン反応組成物が、CoA0.mM〜1mM、 CoA以外のチオール試薬5mM〜100mM、アデノシン三リン酸0.10m M〜1.mM、ルシフェリン0.mM〜1.mM及びマグネシウムイオン2mM 〜15mMをむ水溶液であることを特徴とする請求項33に記載の試験キット。 35.CoA以外のチオール試薬がジチオトレイトールであり、溶液中に濃度5 mM〜100mMで存在することを特徴とする請求項34に記載の試験キット。 36.甲虫ルシフェラーゼを含むと考えられる培養した哺乳類細胞サンプル中の 甲虫ルシフェラーゼの存在をアッセイするための請求項33に記載の試験キット であって、さらにルシフェラーゼ−ルシフェリン反応組成物と別個に、ルシフェ ラーゼ−ルシフェリン反応でルシフェラーゼが活性であるpH及びイオン強度の 水溶液である前記細胞を溶解するための組成物を含み、且つ濃度0.1%〜10 %(m/m)の非イオン洗剤、濃度0.1mM/me〜mM/meの蛋白質性ル シフェラーゼー活性エンハンサー、濃度1mM〜10mMのCoA以外のチオー ル試薬及び濃度1%〜50%(v/v)のグリセロールまたはエチレングリコー ルよりなる組成物を含むことを特徴とする該試験キット。 37.甲虫ルシフェラーゼを合むと考えられる培養した哺乳類細胞サンプル中に 甲虫ルシフェラーゼの存在をアッセイするための請求項34に記載の試験キット であって、さらにルシフェラーゼ−ルシフェリン反応組成物と別個に、ルシフェ ラーゼ−ルシフェリン反応でルシフェラーゼが活性であるpH及びイオン強度の 水溶液である前記細胞を溶解するための組成物を含み、且つ1分子当たりエチレ ニルオキシ単位を平均9〜10個有するオクトキシノール混合物である非イオン 洗剤0.1%〜10%(v/v)、濃度0.1mg/me1〜5mg/meのウ シ胎児血清アルブミン、濃度1.mM〜10mMのジチオトレイトール及び濃度 1%〜50%(v/v)のグリセロールまたはエチレングリコールよりなる組成 物を含むことを特徴とする該試験キット。 38.甲虫ルシフェラーゼを含むと考えられる培養した哺乳類細胞サンアル中に 甲虫ルシフェラーゼの存在をアッセイするための請求項35に記載の試験キット であって、さらにルシフェラーゼ−ルシフェリン反応組成物と別個に、ルシフェ ラーゼ−ルシフェリン反応でルシフェラーゼが活性であるpH及びイオン強度の 水溶液である前記細胞を溶解するための組成物を含み、且つ1分子当たりエチレ ニルオキシ電位を平均9〜10個有するオクトキシノール混合物である非イオン 洗剤0.1%〜10%(v/v)、濃度0.1mg/me〜5me/meのウシ 胎児血清アルブミン、濃度1.mM〜10mMのジチオトレイトール及び濃度1 %〜50%(v/v)のグリセロールまたはエチレングリコールよりなる組成物 を合むことを特徴とする該試験キット。 39.キットの被分析物質である甲虫ルシフェラーゼがPpyralisルシフ ェラーゼであることを特徴とする請求項33〜38のいずれか1項に記載の試験 キット。 40.キットが甲虫ルシフェラーゼ、チオール試薬、ルシフェリン及びマグネシ ウムイオンからなる組成物を合むことを特徴とする、アデノシン三リン酸を含む と考えられるサンプル中のアデノシン三りン酸の存在をアッセイするための試験 キット。 41.組成物が、CoA0.1mM〜1.0mM、CoA以外のチオール試薬5 mM〜200mM及びマグネシウムイオン2mM〜15mMを含む水溶液である ことを特徴とする請求項40に記載の試験キト。 42.CoA以外のチオール試薬がジチオトレイトールであり、溶液中に濃度5 mM〜100mMで存在すろことを特徴とする請求項41に記載の試製キット。 43.甲虫ルシフェラーゼがP.pyralisルシフェラーゼであることを特 徴とする請求項40〜42のいずれか1項に記載の試験キット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US580,371 | 1990-09-10 | ||
US07/580,371 US5283179A (en) | 1990-09-10 | 1990-09-10 | Luciferase assay method |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000400335A Division JP2001224398A (ja) | 1990-09-10 | 2000-12-28 | ルシフェラーゼ組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06500921A true JPH06500921A (ja) | 1994-01-27 |
JP3171595B2 JP3171595B2 (ja) | 2001-05-28 |
Family
ID=24320802
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51753191A Expired - Lifetime JP3171595B2 (ja) | 1990-09-10 | 1991-09-09 | ルシフェラーゼ組成物及び方法 |
JP2000400335A Pending JP2001224398A (ja) | 1990-09-10 | 2000-12-28 | ルシフェラーゼ組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000400335A Pending JP2001224398A (ja) | 1990-09-10 | 2000-12-28 | ルシフェラーゼ組成物及び方法 |
Country Status (10)
Country | Link |
---|---|
US (4) | US5283179A (ja) |
EP (1) | EP0553234B2 (ja) |
JP (2) | JP3171595B2 (ja) |
AT (1) | ATE173298T1 (ja) |
AU (1) | AU649289B2 (ja) |
DE (1) | DE69130482T3 (ja) |
DK (1) | DK0553234T4 (ja) |
ES (1) | ES2126576T5 (ja) |
GR (1) | GR3029352T3 (ja) |
WO (1) | WO1992004468A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008545378A (ja) * | 2005-05-13 | 2008-12-18 | パーキンエルマー ライフ アンド アナリティカル サイエンシス ビー.ブイ. | ルシフェラーゼ検出分析系 |
US7741067B2 (en) | 2002-12-23 | 2010-06-22 | Promega Corporation | Luciferase-based assays |
Families Citing this family (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283179A (en) * | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
GB9224058D0 (en) * | 1992-11-17 | 1993-01-06 | Celsis Ltd | Bioluminescence reagent formulation |
AT401526B (de) * | 1993-02-10 | 1996-09-25 | Scheirer Winfried | Reagenzlösung zur stabilisierung der lumineszenz bei der luciferasemessung |
JP2651651B2 (ja) * | 1993-04-21 | 1997-09-10 | チッソ株式会社 | 蛍酵素ルシフェラーゼ遺伝子 |
US5695928A (en) * | 1993-12-10 | 1997-12-09 | Novartis Corporation | Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction |
US6770446B1 (en) * | 1994-06-14 | 2004-08-03 | Wyeth | Cell systems having specific interaction of peptide binding pairs |
US7255851B2 (en) * | 1994-07-01 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
US6649143B1 (en) | 1994-07-01 | 2003-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Non-invasive localization of a light-emitting conjugate in a mammal |
US5679515A (en) * | 1994-10-03 | 1997-10-21 | Pathogenesis Corporation | Mycobacterial reporter strains and uses thereof |
US5744320A (en) * | 1995-06-07 | 1998-04-28 | Promega Corporation | Quenching reagents and assays for enzyme-mediated luminescence |
US5726041A (en) * | 1995-08-30 | 1998-03-10 | Gentest Corporation | Method for detecting a receptor-ligand complex using a cytochrome P450 reporter gene |
US8349602B1 (en) * | 1996-04-19 | 2013-01-08 | Xenogen Corporation | Biodetectors targeted to specific ligands |
US5798263A (en) * | 1996-09-05 | 1998-08-25 | Promega Corporation | Apparatus for quantifying dual-luminescent reporter assays |
US6602677B1 (en) * | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
US6171809B1 (en) * | 1998-01-29 | 2001-01-09 | Packard Instrument Company | Method and compositions for detecting luciferase biological samples |
CA2263784A1 (en) | 1998-03-23 | 1999-09-23 | Megabios Corporation | Dual-tagged proteins and their uses |
US6183978B1 (en) * | 1998-09-04 | 2001-02-06 | Tropix, Inc. | Luciferase assay, compositions and kits for use in connection therewith |
NL1010224C2 (nl) * | 1998-09-30 | 2000-03-31 | Packard Biosciene B V | Werkwijze voor het detecteren van ATP. |
AU2404500A (en) * | 1999-01-08 | 2000-07-24 | Medical Analysis Systems, Inc. | Compositions and methods for stabilizing thiol-containing biomolecules |
US6410255B1 (en) * | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
JP2001103972A (ja) | 1999-10-06 | 2001-04-17 | Kikkoman Corp | ルシフェリンを再生する能力を有するタンパク質をコードする遺伝子、新規な組み換え体dna及びルシフェリンを再生する能力を有するタンパク質の製造法 |
US20040214227A1 (en) * | 1999-12-22 | 2004-10-28 | Erik Joly | Bioluminescence resonance energy transfer (bret) fusion molecule and method of use |
US6502774B1 (en) * | 2000-03-08 | 2003-01-07 | J + L Fiber Services, Inc. | Refiner disk sensor and sensor refiner disk |
US6927851B2 (en) * | 2000-03-31 | 2005-08-09 | Neogen Corporation | Methods and apparatus to improve the sensitivity and reproducibility of bioluminescent analytical methods |
US6667287B2 (en) * | 2000-04-20 | 2003-12-23 | Colgate-Palmolive Company | Light duty cleaning composition comprising an amine oxide and polyacrylic acid homopolymer |
MXPA02010446A (es) * | 2000-04-24 | 2003-04-25 | Wyeth Corp | Sistemas celulares novedosos, con interaccion especifica de los pares que se unen a los peptidos. |
WO2001093930A1 (en) * | 2000-06-02 | 2001-12-13 | The University Of Utah Research Foundation | Active needle devices with integrated functionality |
US7118878B1 (en) | 2000-06-09 | 2006-10-10 | Promega Corporation | Method for increasing luminescence assay sensitivity |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
US7879540B1 (en) | 2000-08-24 | 2011-02-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
US20030157643A1 (en) * | 2000-08-24 | 2003-08-21 | Almond Brian D | Synthetic nucleic acids from aquatic species |
CA2427472A1 (en) | 2000-10-27 | 2002-06-06 | Tae Kook Kim | Double and triple readout assay systems |
US6660489B2 (en) | 2000-12-01 | 2003-12-09 | Becton, Dickinson And Company | ATP extraction method |
CA2328684A1 (en) * | 2000-12-15 | 2002-06-15 | Yahia Gawad | Photon-triggered luminescent assay |
US6800453B2 (en) * | 2001-01-23 | 2004-10-05 | President And Fellows Of Harvard College | Nucleic-acid programmable protein arrays |
US7666615B2 (en) * | 2001-01-29 | 2010-02-23 | Hemogenix, Inc. | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
US7354730B2 (en) * | 2002-01-29 | 2008-04-08 | Hemogenix, Inc. | High-throughput assay of hematopoietic stem and progenitor cell proliferation |
EP1364197B1 (en) * | 2001-01-29 | 2010-04-14 | Ivan N. Rich | ATP-based assay for the determination of the proliferation status of hematopoietic stem and progenitor cells |
US7989178B2 (en) * | 2001-01-29 | 2011-08-02 | Hemogenix, Inc. | Colony assay miniaturization with enumeration output |
US7083911B2 (en) * | 2001-02-16 | 2006-08-01 | Promega Corporation | Method for detection of ATP |
US6858773B2 (en) * | 2001-04-20 | 2005-02-22 | Xenogen Corporation | Transgenic mice comprising transcription control elements associated with mouse eosinophil peroxidase expression |
WO2003016839A2 (en) * | 2001-08-15 | 2003-02-27 | Xenogen Corporation | Modified railroad worm red luciferase coding sequences |
US7268229B2 (en) * | 2001-11-02 | 2007-09-11 | Promega Corporation | Compounds to co-localize luminophores with luminescent proteins |
AU2002348287A1 (en) * | 2001-11-16 | 2003-06-10 | Pierce Biotechnology, Inc. | Phosphine-containing formulations for chemiluminescent luciferase assays |
EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
WO2003060078A2 (en) * | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
US20040044063A1 (en) * | 2002-05-31 | 2004-03-04 | Brent Stockwell | SMA therapy and cell based assay for identifying therapies |
EP1539997A4 (en) * | 2002-08-21 | 2007-04-25 | Ivan N Rich | HIGH-PERFORMANCE PROLIFERATION ASSAY OF HEMATOPOIETIC STRAINS AND PROGENITOR CELLS |
JP2004089117A (ja) * | 2002-09-03 | 2004-03-25 | Toyo B-Net Co Ltd | ルシフェラーゼ検出試薬キット及び当該キットを使用したルシフェラーゼ検出方法 |
ATE487797T1 (de) | 2002-09-06 | 2010-11-15 | Promega Corp | Verfahren zum nachweis von transferase- enzymaktivität |
ATE513838T1 (de) * | 2002-09-20 | 2011-07-15 | Promega Corp | Auf lumineszenz basierende verfahren und sonden zur messung der cytochrom-p450-aktivität |
US7413874B2 (en) * | 2002-12-09 | 2008-08-19 | University Of Miami | Nucleic acid encoding fluorescent proteins from aquatic species |
WO2004067728A2 (en) * | 2003-01-17 | 2004-08-12 | Ptc Therapeutics | Methods and systems for the identification of rna regulatory sequences and compounds that modulate their function |
EP1592805A1 (en) * | 2003-02-12 | 2005-11-09 | Promega Corporation | Methods and kits for dual enzymatic assays whereby light is quenched from luminescent reactions |
US7390670B2 (en) | 2003-02-20 | 2008-06-24 | Lumigen, Inc. | Signalling compounds and methods for detecting hydrogen peroxide |
US6970240B2 (en) * | 2003-03-10 | 2005-11-29 | Applera Corporation | Combination reader |
DE10315640A1 (de) | 2003-04-04 | 2004-10-14 | Ignatov, Konstantin | Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung |
US7494781B1 (en) * | 2003-05-12 | 2009-02-24 | Charm Sciences, Inc. | Sensitive method for detecting low levels of ATP |
US7132249B1 (en) | 2003-05-12 | 2006-11-07 | Charm Sciences, Inc. | Method of determining allergenic food on surfaces |
US7727752B2 (en) * | 2003-07-29 | 2010-06-01 | Life Technologies Corporation | Kinase and phosphatase assays |
CA2445420A1 (en) | 2003-07-29 | 2005-01-29 | Invitrogen Corporation | Kinase and phosphatase assays |
EP1687323A4 (en) | 2003-08-08 | 2009-08-12 | Life Technologies Corp | METHODS AND COMPOSITIONS FOR DIRECT CLONING OF NUCLEIC ACID MOLECULES |
EP1687399A4 (en) * | 2003-10-03 | 2007-09-05 | Univ Michigan Tech | MODIFIED LUCIFERASE |
DE602004027538D1 (de) | 2003-12-01 | 2010-07-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
US7422868B2 (en) * | 2004-07-02 | 2008-09-09 | Promega Corporation | Microbial ATP extraction and detection system |
US7728118B2 (en) * | 2004-09-17 | 2010-06-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
TWI290956B (en) * | 2004-12-31 | 2007-12-11 | Ind Tech Res Inst | Luminescence-based recipe and device using the same |
US7939286B2 (en) * | 2005-03-07 | 2011-05-10 | Targeting Systems | Enhancing a luminescent signal |
US20060214141A1 (en) * | 2005-03-23 | 2006-09-28 | Yankielun Norbert E | Luminescent illumination adjunct for night vision |
US20060234323A1 (en) * | 2005-04-18 | 2006-10-19 | Cali James J | Luminescent ATP detection with extended linearity |
EP2277872B1 (en) * | 2005-05-31 | 2016-03-23 | Promega Corporation | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions |
KR20080028964A (ko) | 2005-06-27 | 2008-04-02 | 엑셀리시스, 인코포레이티드 | 피라졸계 lxr 변조제 |
CN101501187A (zh) * | 2006-06-06 | 2009-08-05 | 田纳西大学研究基金会 | 富含赘生干细胞的组合物及包含其的方法 |
US8178316B2 (en) * | 2006-06-29 | 2012-05-15 | President And Fellows Of Harvard College | Evaluating proteins |
WO2008045121A1 (en) * | 2006-10-13 | 2008-04-17 | Charm Sciences, Inc. | Method and apparatus for reducing luminescent test result interferences |
JP2008113620A (ja) * | 2006-11-07 | 2008-05-22 | Toyobo Co Ltd | ルシフェラーゼの発光方法 |
DE102006054562A1 (de) * | 2006-11-20 | 2008-05-21 | Bayer Healthcare Ag | Verfahren zum Nachweis von Pyrophosphat mit Biolumineszenz Detektion |
WO2008074100A1 (en) | 2006-12-21 | 2008-06-26 | Gene Stream Pty Ltd | Bioluminescent assays utilising secreted luciferases |
WO2008103474A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
WO2008109459A1 (en) | 2007-03-02 | 2008-09-12 | University Of Massachusetts | Luciferins |
US20080248511A1 (en) * | 2007-03-26 | 2008-10-09 | Promega Corporation | Methods to quench light from optical reactions |
US20090081715A1 (en) * | 2007-09-07 | 2009-03-26 | Cobalt Technologies, Inc., A Delaware Corporation | Engineered Light-Emitting Reporter Genes |
JP5332178B2 (ja) * | 2007-11-02 | 2013-11-06 | 東洋紡株式会社 | 多色ルシフェラーゼの検出方法 |
WO2009061837A1 (en) * | 2007-11-05 | 2009-05-14 | Novostem Therapeutics Inc | Neoplastic stem cell system and method |
CA2721076A1 (en) | 2008-04-09 | 2009-10-15 | Cobalt Technologies, Inc. | Immobilized product tolerant microorganisms |
JP5597200B2 (ja) * | 2008-08-18 | 2014-10-01 | プロメガ コーポレイション | ルミネッセンスを生じる化合物およびチトクロムp4503a酵素を検出するための方法 |
DK2414507T3 (da) | 2009-04-03 | 2014-08-25 | Medical Res Council | Mutanter af aktiveringsinduceret cytidin-deaminase (aid) og til anvendelsesfremgangsmåder |
CN102482690A (zh) | 2009-06-26 | 2012-05-30 | 钴技术有限公司 | 生物产物生产的集成系统和方法 |
US8569002B2 (en) | 2010-10-20 | 2013-10-29 | The Board Of Regents Of The University Of Texas System | Multiplexed luciferase reporter assay systems |
JP5863338B2 (ja) | 2011-08-25 | 2016-02-16 | 株式会社東芝 | プラスミド型ベクター、遺伝子プロモーター活性の検出方法、及びアッセイキット |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
WO2015116867A1 (en) | 2014-01-29 | 2015-08-06 | Promega Corporation | Quinone-masked probes as labeling reagents for cell uptake measurements |
JP6862368B2 (ja) * | 2015-06-25 | 2021-04-21 | プロメガ コーポレイションPromega Corporation | チエノピロール化合物、及びそのOplophorus由来ルシフェラーゼの阻害剤としての使用 |
AU2016282869B2 (en) | 2015-06-26 | 2022-08-18 | Sanofi Biotechnology SAS | Monoclonal anti-IL-1RAcP antibodies |
US11015176B2 (en) | 2016-03-11 | 2021-05-25 | National Institute Of Advanced Industrial Science And Technology | Nucleic acid encoding a luminescent enzyme protein |
EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
EP3562823B1 (en) | 2016-12-28 | 2023-02-08 | Promega Corporation | Functionalized nanoluc inhibitors |
EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
CN111089859A (zh) * | 2018-10-23 | 2020-05-01 | 北京中医药大学 | 新型三磷酸腺苷生物发光测定方法及其用途 |
RU2744869C2 (ru) * | 2019-08-08 | 2021-03-16 | Общество с ограниченной ответственностью "ПЛАНТА" | Метод и реактивы для детекции активности люциферазы |
CN113030052B (zh) * | 2021-03-18 | 2022-10-21 | 中国科学院华南植物园 | 一种香蕉采后果实eATP水平的检测方法 |
WO2022235929A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
CN114350626A (zh) * | 2021-12-21 | 2022-04-15 | 合肥巅峰生物科技有限公司 | 一种荧光素酶冻干粉稀释反应液 |
CN114736949B (zh) * | 2022-03-22 | 2024-03-01 | 药科元(上海)生物技术有限公司 | 一种萤火虫荧光素酶报告基因检测试剂盒 |
WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE428379B (sv) * | 1978-05-31 | 1983-06-27 | Lkb Produkter Ab | Bioluminiscens bestemning av atp och reagens herfor |
DE2828658C3 (de) * | 1978-06-29 | 1981-10-22 | Lkb-Produkter Ab, Stockholm | Verfahren zur photometrischen Bestimmung der Untereinheit B der Creatinkinase und Reagens hierfür |
US4234681A (en) * | 1978-07-21 | 1980-11-18 | The Regents Of The University Of California | Immobolized light emitting systems |
US4614712A (en) * | 1983-02-25 | 1986-09-30 | The Upjohn Company | Immunoassays with luciferase labeled ligands or receptors |
US4665022A (en) * | 1984-02-17 | 1987-05-12 | The Regents Of The University Of California | Bioluminescent assay reagent and method |
FR2566798B1 (fr) * | 1984-06-27 | 1986-12-12 | Centre Nat Rech Scient | Membrane porteuse de la luciferase pour le dosage de l'atp et son procede de production |
JPS6163855A (ja) * | 1984-09-05 | 1986-04-02 | Fuji Photo Film Co Ltd | 静電写真用液体現像剤 |
DK258787D0 (da) * | 1987-05-21 | 1987-05-21 | Foss Electric As N | Fremgangsmaade til bestemmelse af bakteriekoncentration i en proeve |
GB8722252D0 (en) * | 1987-09-22 | 1987-10-28 | Brewing Res Found | Atp extraction |
US5283179A (en) * | 1990-09-10 | 1994-02-01 | Promega Corporation | Luciferase assay method |
-
1990
- 1990-09-10 US US07/580,371 patent/US5283179A/en not_active Expired - Lifetime
-
1991
- 1991-09-09 AU AU88583/91A patent/AU649289B2/en not_active Ceased
- 1991-09-09 ES ES91919421T patent/ES2126576T5/es not_active Expired - Lifetime
- 1991-09-09 JP JP51753191A patent/JP3171595B2/ja not_active Expired - Lifetime
- 1991-09-09 DE DE69130482T patent/DE69130482T3/de not_active Expired - Lifetime
- 1991-09-09 AT AT91919421T patent/ATE173298T1/de not_active IP Right Cessation
- 1991-09-09 DK DK91919421T patent/DK0553234T4/da active
- 1991-09-09 WO PCT/US1991/006474 patent/WO1992004468A1/en active IP Right Grant
- 1991-09-09 EP EP91919421A patent/EP0553234B2/en not_active Expired - Lifetime
-
1994
- 1994-01-31 US US08/189,558 patent/US5650289A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/485,834 patent/US5641641A/en not_active Expired - Lifetime
-
1997
- 1997-04-09 US US08/831,781 patent/US5814471A/en not_active Expired - Lifetime
-
1999
- 1999-02-10 GR GR990400439T patent/GR3029352T3/el unknown
-
2000
- 2000-12-28 JP JP2000400335A patent/JP2001224398A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7741067B2 (en) | 2002-12-23 | 2010-06-22 | Promega Corporation | Luciferase-based assays |
US8361739B2 (en) | 2002-12-23 | 2013-01-29 | Promega Corporation | Luciferase-based assays |
JP2008545378A (ja) * | 2005-05-13 | 2008-12-18 | パーキンエルマー ライフ アンド アナリティカル サイエンシス ビー.ブイ. | ルシフェラーゼ検出分析系 |
Also Published As
Publication number | Publication date |
---|---|
GR3029352T3 (en) | 1999-05-28 |
US5283179A (en) | 1994-02-01 |
ATE173298T1 (de) | 1998-11-15 |
DK0553234T3 (da) | 1999-07-26 |
EP0553234A1 (en) | 1993-08-04 |
AU8858391A (en) | 1992-03-30 |
AU649289B2 (en) | 1994-05-19 |
DE69130482D1 (de) | 1998-12-17 |
EP0553234B1 (en) | 1998-11-11 |
DE69130482T2 (de) | 1999-05-27 |
JP3171595B2 (ja) | 2001-05-28 |
US5641641A (en) | 1997-06-24 |
US5814471A (en) | 1998-09-29 |
ES2126576T3 (es) | 1999-04-01 |
DE69130482T3 (de) | 2006-05-04 |
DK0553234T4 (da) | 2005-08-01 |
EP0553234A4 (ja) | 1995-08-02 |
ES2126576T5 (es) | 2005-12-01 |
EP0553234B2 (en) | 2005-07-13 |
WO1992004468A1 (en) | 1992-03-19 |
US5650289A (en) | 1997-07-22 |
JP2001224398A (ja) | 2001-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06500921A (ja) | ルシフェラーゼ組成物及び方法 | |
JP4125600B2 (ja) | 改良されたatp検出法 | |
EP1588143B1 (en) | Improved luciferase-based assays | |
JP5254008B2 (ja) | ルシフェラーゼ検出分析系 | |
US6171809B1 (en) | Method and compositions for detecting luciferase biological samples | |
JP2007330270A6 (ja) | 改良されたatp検出法 | |
Ford et al. | Improvements in the application of firefly luciferase assays | |
JP2539225B2 (ja) | グルコ−ス定量用安定化液体酵素組成物、それを用いる試薬キット及び定量方法 | |
JPH10502538A (ja) | 微生物学的試験方法および試薬 | |
Dı́az et al. | Horseradish peroxidase sol–gel immobilized for chemiluminescence measurements of alkaline-phosphatase activity | |
US20040101922A1 (en) | Method for detecting transferase enzymatic activity | |
Soldatkin et al. | Microbiosensor based on glucose oxidase and hexokinase co-immobilised on platinum microelectrode for selective ATP detection | |
EP1228239A2 (en) | Assay of micro-organisms in cell cultures | |
JPH0847399A (ja) | 生物発光の測定方法 | |
Marcaida et al. | Determination of intracellular ATP in primary cultures of neurons | |
JP2008536519A (ja) | 延長した直線を用いる発光atp検出 | |
US20040219622A1 (en) | Phosphine-containing formulations for chemiluminescent luciferase assays | |
SU1041568A1 (ru) | Реагент дл определени аденозин-5-трифосфата | |
KR20200082077A (ko) | 세포 내 atp 검출용 조성물, 및 이를 이용한 문화재 또는 기록물의 미생물 오염도 측정 방법 | |
JPS61289900A (ja) | クレアチンキナ−ゼ定量用試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090323 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100323 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100323 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110323 Year of fee payment: 10 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120323 Year of fee payment: 11 |